subject have significantly impair hepatic function at the 'end of treatment visit of their core study or at visit 1 if re-assessed alanine aminotransferase alt 5 x upper limit of normal uln or total bilirubin tbl 2 x uln or alt or aspartate aminotransferase ast 3 x uln and tbl 2 x uln or international normalized ratio inr 1.5 this criterion can only be confirm once the laboratory result be available subject that enter the study and be late found not to meet this criterion should be withdraw from the study 